List of Excipients in Branded Drug NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WG Critical Care LLC	NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE	norepinephrine bitartrate	44567-640	HYDROCHLORIC ACID
WG Critical Care LLC	NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE	norepinephrine bitartrate	44567-640	SODIUM CHLORIDE
WG Critical Care LLC	NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE	norepinephrine bitartrate	44567-640	SODIUM HYDROXIDE

Norepinephrine Bitartrate in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 8, 2026

Norepinephrine bitartrate in sodium chloride is a ready-to-use intravenous vasopressor formulation for acute hypotension and septic shock. Its commercial value depends less on active-ingredient exclusivity than on formulation stability, container compatibility, supply reliability, hospital workflow, and shortage resilience. The strongest product strategy is a preservative-free, ready-to-administer bag with validated oxygen-control, light protection, and low-sorption packaging.

What is norepinephrine bitartrate in sodium chloride?

Norepinephrine bitartrate in sodium chloride is an intravenous solution containing norepinephrine bitartrate in 0.9% sodium chloride. It is used to raise blood pressure in adults with severe acute hypotension, including hypotension associated with septic shock. FDA labeling identifies norepinephrine as a potent vasoconstrictor administered by continuous intravenous infusion after appropriate volume replacement where clinically indicated. [1]

Typical commercial presentations include:

Attribute	Common product configuration
Active ingredient	Norepinephrine bitartrate
Diluent	0.9% sodium chloride
Dosage form	Sterile intravenous solution
Administration	Continuous IV infusion
Common fill volume	250 mL
Common strength	4 mg/250 mL, expressed as norepinephrine bitartrate
Alternative strength	8 mg/250 mL
Use setting	ICU, emergency department, operating room, transport and critical-care units
Container	Flexible IV bag, usually single-dose or single-use
Preservative profile	Preservative-free presentation is commercially preferred

The product is a hospital injectable rather than a retail prescription medicine. Purchasing decisions are made by health systems, group purchasing organizations, distributors and pharmacy departments.

What excipients are used in norepinephrine bitartrate in sodium chloride?

The core excipient system is intentionally simple: sodium chloride and water for injection. The formulation may also contain pH-adjusting agents or other inactive ingredients depending on the manufacturer and presentation. The final composition must be verified against the applicable FDA-approved label and DailyMed entry. [1,2]

Sodium chloride

Sodium chloride provides the isotonic vehicle. A 0.9% sodium chloride solution has an approximate sodium chloride concentration of 9 mg/mL and is widely accepted for peripheral and central IV administration, subject to the product label and clinical circumstances.

Its commercial advantages are substantial:

• Familiarity to hospital pharmacists and nurses.
• Compatibility with standard infusion protocols.
• Broad availability of IV administration equipment.
• Lower formulation complexity than dextrose-based alternatives.
• Reduced need for pharmacy compounding before use.

Sodium chloride also creates a differentiated product category compared with norepinephrine in 5% dextrose. Hospitals may prefer the sodium chloride presentation when avoiding additional glucose load or aligning with fluid-management protocols.

Water for injection

Water for injection is the solvent. Sterility, bacterial endotoxin control, particulate control and container-closure integrity are central quality attributes for the finished product.

pH control

Norepinephrine is chemically vulnerable to oxidation. Commercial labels commonly identify pH control as relevant to stability, although the precise agent and concentration vary by product. A manufacturer should not assume that a pH-adjusting excipient can be copied from another product without evaluating:

• Norepinephrine degradation products.
• Color formation.
• Bitterness or ionic effects are not relevant to IV use, but osmolality and compatibility are.
• Container interaction.
• Extractables and leachables.
• Stability after simulated in-use exposure.

Sodium metabisulfite and other antioxidants

Some norepinephrine concentrate products contain sodium metabisulfite or another antioxidant. A ready-to-use sodium chloride premix should not automatically include the same antioxidant system. The decision depends on the target stability profile, regulatory precedent, sulfite sensitivity considerations and the selected container.

A sulfite-containing formulation may reduce oxidative degradation, but it can create additional labeling and safety considerations. FDA labeling for sulfite-containing injectable products warns that sulfites may cause allergic-type reactions, including anaphylactic symptoms and life-threatening episodes in susceptible individuals, particularly those with asthma. [3]

For a new commercial product, the preferred strategy is to determine whether adequate shelf life can be achieved through:

1. Controlled pH.
2. Low headspace oxygen.
3. Nitrogen or inert-gas processing.
4. Oxygen-barrier container materials.
5. Light protection.
6. Tight control of metal ions and peroxide impurities.
7. Validated manufacturing and storage conditions.

An antioxidant should be added only when the benefit is demonstrated through comparative stability data.

How should the excipient strategy address norepinephrine oxidation?

The principal technical risk is oxidative degradation. Norepinephrine solutions can darken or develop degradation products when exposed to oxygen, light, elevated temperature or trace metals.

Recommended formulation-development program

Development variable	Commercial objective
pH range	Maximize chemical stability while preserving physiological acceptability
Oxygen exposure	Reduce initial dissolved and headspace oxygen
Light exposure	Establish whether secondary packaging is required
Trace metals	Evaluate chelation and raw-material controls
Container material	Minimize oxygen ingress and drug sorption
Terminal sterilization	Determine whether aseptic processing is required
In-use period	Support safe administration after bag connection
Temperature excursions	Define shipping and hospital-storage tolerance
Freeze-thaw exposure	Establish distribution robustness
Particulates	Protect against visible and subvisible contamination

The most defensible technical package combines real-time and accelerated stability with forced-degradation studies. The study design should evaluate assay, related substances, color, pH, osmolality, particulate matter, sterility and container integrity.

Container and closure opportunities

The container may create more commercial differentiation than the excipient list.

Potential configurations include:

• Multilayer polyolefin bag.
• Non-DEHP bag.
• Low-sorption tubing-compatible container.
• High oxygen-barrier film.
• Secondary overwrap with light protection.
• Ready-to-connect port design.
• Unit-of-use bag with barcoding and tamper evidence.

A low-sorption container is important because norepinephrine is delivered at low concentrations and may interact with some plastics or administration sets. Compatibility testing should cover the full system, not only the primary bag.

What formulations are protected by patents?

Norepinephrine bitartrate is an established active ingredient with a long clinical history. The active molecule, its bitartrate salt and standard sodium chloride vehicle are unlikely to support broad new-compound exclusivity.

The potentially protectable elements are narrower:

Claim area	Patent potential	Commercial relevance
New chemical entity	Low	Norepinephrine is established
Bitartrate salt	Low for broad claims	Historical pharmaceutical form
Sodium chloride vehicle	Low	Standard IV diluent
Specific pH range	Moderate	Depends on unexpected stability or safety benefit
Antioxidant-free formulation	Moderate	Requires demonstrated stability advantage
Oxygen-controlled manufacturing	Moderate	May support process claims
Low-oxygen container system	Moderate	Stronger if linked to shelf-life improvement
Flexible bag architecture	Moderate	Potentially valuable but design-around risk is high
Extended room-temperature stability	Moderate	Commercially important
Method of treating hypotension	Low to moderate	Method-of-use scope may be limited
Automated compounding or pharmacy workflow	Moderate	More likely to support operational differentiation
Combination with infusion-control technology	Moderate	May support device or system claims

A formulation patent should avoid claiming only the presence of norepinephrine, sodium chloride and water. Such claims face substantial prior-art and obviousness exposure. Stronger claims would connect composition and performance, for example:

• A defined pH range with a demonstrated reduction in oxidative impurities.
• A defined dissolved-oxygen specification.
• A container with measured oxygen transmission limits.
• A shelf life that exceeds conventional presentations under specified storage conditions.
• A preservative-free formulation with stability comparable to an antioxidant-containing product.
• A validated combination of formulation, bag material and overwrap.

What is the Orange Book status of norepinephrine in sodium chloride?

Norepinephrine products may be marketed through different FDA approval pathways, including abbreviated new drug applications and potentially other application types for ready-to-use presentations. Orange Book listing must be assessed at the individual product and application level. The Orange Book lists patents and exclusivity associated with eligible approved applications; it does not create patent protection for every generic product. [4]

For an established injectable such as norepinephrine in sodium chloride, the key regulatory questions are:

1. Is the product approved under an ANDA, NDA or another pathway?
2. Does the application have listed patents?
3. Is pediatric or other regulatory exclusivity active?
4. Are patents directed to the formulation, container or method of use?
5. Does the proposed product require a Paragraph IV certification?
6. Is the reference listed drug currently marketed?

A developer should treat the base product as a low-exclusivity molecule unless an identified formulation or device patent creates a meaningful barrier.

When does norepinephrine in sodium chloride lose exclusivity?

Norepinephrine bitartrate itself has no meaningful new-molecule exclusivity remaining. The commercial exclusivity question concerns product-specific patents, regulatory exclusivity and supply contracts.

Exclusivity type	Expected position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not generally applicable
Standard generic competition	Established or legally available, depending on product
Formulation patents	Product-specific; must be checked individually
Device or container patents	Potentially relevant
Pediatric exclusivity	Not assumed without a specific FDA record
Market exclusivity from shortage status	Not a conventional patent right
Contractual hospital preference	Commercial, not statutory

The absence of broad active-ingredient exclusivity means that an entrant can generally compete through an approved generic, a 505(b)(2) product where appropriate, or a differentiated ready-to-use presentation. The main barriers are regulatory approval, manufacturing validation, quality systems, procurement access and clinical supply performance.

Which companies are competing in norepinephrine premix products?

The competitive field includes branded pharmaceutical manufacturers, generic injectable companies, contract manufacturers and hospital-focused suppliers. Product availability changes with shortages, discontinuations, acquisitions and manufacturing events.

Relevant competitor groups include:

• Pfizer and Hospira-branded injectable operations.
• Baxter and other large hospital-infusion suppliers.
• Hikma Pharmaceuticals.
• Fresenius Kabi.
• Sagent Pharmaceuticals and related injectable portfolios.
• ICU Medical and other hospital-infusion suppliers.
• Smaller ANDA holders and contract manufacturers.

The exact competitive set should be mapped using current FDA approval records, National Drug Code data, DailyMed, wholesaler listings and hospital-contract data. Product-level competition is often more fragmented than the branded name suggests because multiple companies may sell the same strength through different channels.

What commercial opportunities exist for norepinephrine in sodium chloride?

The clearest opportunities are operational rather than pharmacological.

Ready-to-use ICU bags

Ready-to-use bags eliminate or reduce bedside or pharmacy dilution. Benefits include:

• Faster administration.
• Lower compounding workload.
• Lower risk of dilution errors.
• More consistent concentration.
• Better support for emergency department and transport use.
• Reduced manipulation of a high-alert medication.

These benefits can support premium pricing if the product has reliable availability and a strong health-economic case.

Shortage-resilient supply

Norepinephrine is a high-priority hospital medicine. FDA shortage records have historically shown that injectable vasopressors can face supply pressure because of concentrated manufacturing and limited redundancy. [5]

A commercial entrant can differentiate through:

• Dual API sourcing.
• More than one fill-finish site.
• Domestic or regional safety stock.
• Multiple bag sizes.
• Transparent allocation policies.
• Validated contingency manufacturing.
• Shorter replenishment lead times.

Supply reliability may be more valuable to hospitals than a marginal price reduction.

Multiple concentrations

A practical portfolio could include:

Presentation	Primary use case
4 mg/250 mL	Standard adult infusion protocols
8 mg/250 mL	Fluid-restricted patients and higher-dose protocols
Smaller-volume bag	Transport, emergency use and limited-access settings
Concentrate vial	Pharmacy compounding and institutional protocols
Sodium chloride bag	Glucose-avoidance and standard ICU use
Dextrose bag	Institutions with established dextrose protocols

Each additional concentration increases regulatory, validation and inventory complexity. The initial launch should focus on the concentration with the strongest protocol adoption and hospital demand.

Closed-system and barcode integration

A bag with a robust barcode, standardized concentration and compatibility with smart pumps can support hospital formulary adoption. Opportunities include:

• GS1-compliant unit-of-use identification.
• Bedside barcode medication administration.
• Smart-pump drug-library integration.
• Clear concentration labeling.
• Distinctive bag design to reduce selection errors.
• Tamper-evident packaging.

These features generally provide commercial differentiation rather than pharmaceutical patent exclusivity.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate. The product is technically simpler than a biologic or complex drug-delivery system, but injectable quality requirements are demanding.

Key barriers include:

1. Sterile manufacturing capacity.
2. Aseptic filling or validated terminal sterilization.
3. Container-closure integrity.
4. Low-bioburden and endotoxin control.
5. Stability against oxidation.
6. Extractables and leachables qualification.
7. Drug-bag and administration-set compatibility.
8. Validated shipping and temperature-excursion data.
9. Consistent API supply.
10. FDA inspection readiness.

The strongest defensible position is likely a combined formulation-and-container estate supported by comparative stability data. Process patents may add value, but they are vulnerable if competitors can reach the same product through different oxygen-control or packaging methods.

How does norepinephrine in sodium chloride compare with norepinephrine in dextrose?

Factor	Sodium chloride presentation	Dextrose presentation
Primary vehicle	0.9% sodium chloride	5% dextrose
Hospital familiarity	Very high	Very high
Glucose load	Avoided	Present
Fluid-management fit	Often favorable	May fit established ICU protocols
Oxidation strategy	Requires controlled stability program	Same core oxidation concern
Commercial differentiation	Fluid and workflow profile	Protocol and legacy use
Formulation complexity	Low	Low
Patent strength	Generally limited	Generally limited
Procurement driver	Availability, price, shortage resilience	Availability, price, protocol fit

Neither vehicle alone creates a strong patent barrier. The commercial advantage depends on institutional protocols, clinical preference, inventory and supply continuity.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge is relevant only if the proposed product references an approved application with a listed patent. For a mature norepinephrine premix, the likely risks are product-specific rather than molecule-wide.

Potential dispute areas include:

• Stability-enhancing pH ranges.
• Preservative-free compositions.
• Antioxidant systems.
• Oxygen-reduced manufacturing.
• Bag materials.
• Container-closure systems.
• Method-of-use claims.
• Device integration claims.

A generic applicant should conduct a product-by-product Orange Book review and freedom-to-operate analysis before selecting a reference product. Patent litigation risk is likely lower for a conventional sodium chloride formulation than for a formulation that copies a patented oxygen-control package or proprietary bag design.

What licensing deals could create value?

Licensing opportunities are more likely to involve manufacturing and distribution than core drug rights.

Potential deal structures include:

• API supply and dual-source agreements.
• Regional commercialization licenses.
• Contract fill-finish partnerships.
• Hospital-distribution agreements.
• Co-development of high-barrier IV bags.
• Licensing of oxygen-barrier film or closure technology.
• Shared shortage-response capacity.
• Private-label supply for group purchasing organizations.

A formulation owner may license the product to a large hospital supplier with established distribution rather than build a standalone commercial organization. The value of the deal would depend on approved status, manufacturing capacity, supply guarantees and hospital-contract access.

How strong is the patent estate for norepinephrine bitartrate in sodium chloride?

The base patent estate is weak for broad composition claims because the active ingredient, salt and sodium chloride vehicle are established technologies. A stronger estate would require a specific technical result that is difficult to design around.

Relative patent-strength assessment

Patent category	Relative strength
Norepinephrine composition of matter	Very low
Bitartrate salt	Low
Sodium chloride vehicle	Very low
Broad ready-to-use premix	Low
Defined antioxidant-free formulation	Moderate if supported by data
Oxygen-controlled packaging	Moderate
Integrated bag and administration system	Moderate
Manufacturing process	Low to moderate
Extended stability claim	Moderate if unexpected and reproducible
Method of treating shock	Low to moderate

Regulatory exclusivity and supply performance are more important than patent strength for most commercial strategies.

What generic launch scenarios exist?

Conventional ANDA launch

A conventional generic can compete on price and availability. The main risks are limited differentiation, hospital-contract pressure and vulnerability to manufacturing interruptions.

Differentiated ready-to-use launch

A ready-to-use sodium chloride bag can compete on labor savings, medication safety and emergency readiness. It may justify a premium if supported by hospital economic data.

Dual-vehicle portfolio

A supplier can offer both sodium chloride and dextrose presentations to secure protocol coverage across hospitals. This approach increases inventory but reduces dependence on one institutional preference.

Shortage-focused launch

A company with redundant manufacturing and strong supply controls can target hospitals affected by intermittent shortages. The commercial message should focus on continuity, allocation transparency and validated capacity.

Key Takeaways

• Norepinephrine bitartrate in sodium chloride is a mature injectable with limited active-ingredient patent value.
• The principal formulation challenge is oxidative stability.
• The core excipient system is sodium chloride and water for injection, with pH control or antioxidant strategy determined by product-specific stability data.
• Preservative-free, ready-to-use bags are commercially attractive because they reduce compounding and administration burden.
• Oxygen-control processing, light protection and container selection are the most relevant technical differentiation points.
• The strongest patent opportunity is a narrow formulation-and-container combination tied to unexpected stability or shelf-life performance.
• Orange Book and Paragraph IV risk must be assessed for each reference application, not inferred from the molecule.
• Supply reliability, shortage resilience, hospital distribution and barcode-compatible packaging are likely to drive commercial value more than patent exclusivity.
• Sodium chloride and dextrose presentations should be treated as complementary portfolio products.
• A successful entrant needs sterile manufacturing capacity, API redundancy, validated container compatibility and access to hospital procurement channels.

FAQs About Norepinephrine Bitartrate in Sodium Chloride

Is norepinephrine bitartrate in sodium chloride a generic drug?

It can be marketed through a generic or other FDA approval pathway, depending on the specific product and application. The approval pathway must be confirmed from current FDA records.

Does norepinephrine in sodium chloride contain sodium metabisulfite?

The answer depends on the manufacturer and product. Some norepinephrine formulations use sulfite antioxidants, while a ready-to-use premix may use a different stability strategy. The applicable FDA label controls.

What is the main stability problem with norepinephrine premix bags?

Oxidation is the principal concern. Oxygen, light, heat, trace metals and container permeability can accelerate degradation and discoloration.

Can a company patent a norepinephrine sodium chloride bag?

A broad claim covering norepinephrine, sodium chloride and water is likely vulnerable. Narrow claims covering a defined pH, oxygen specification, container structure or unexpected stability result may have stronger prospects.

Why do hospitals buy premixed norepinephrine instead of concentrate?

Premixed bags can reduce dilution steps, pharmacy workload, dosing variability and time to administration. Their commercial value increases during staffing constraints and injectable-drug shortages.

References

1. DailyMed. (n.d.). Norepinephrine bitartrate injection prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Sulfite sensitivity labeling for injectable drug products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Drug shortages: Norepinephrine injection. https://www.accessdata.fda.gov/scripts/drugshortages/